Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392704 · ClinicalTrials.gov registry record · Phase 2
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00392704 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 60 participants.
The verdict
NCT00392704, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Two new cancer treatment drugs called targeted therapies will be added to standard treatment for head and neck cancer to see if an improvement can be made in the effectiveness of treatment for this type of cancer. Treatment will include chemotherapy, radiation therapy and targeted therapy taken over a period of 4 months.
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- RADIATION Radiation Therapy
- DRUG 5-FU
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392704
The ClinicalTrials.gov registry entry for NCT00392704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00392704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392704 about?
NCT00392704 is a clinical study titled "Treatment of Head & Neck Cancer With Chemotherapy and Radiation". Two new cancer treatment drugs called targeted therapies will be added to standard treatment for head and neck cancer to see if an improvement can be made in the effectiveness of treatment for this type of cancer. Treatment will include chemotherapy, radiation therapy and targeted therapy taken over...
What is the current status of trial NCT00392704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-12. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00392704?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION), 5-FU (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00392704?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.